Skip to content

Janux Therapeutics JANX Net Change in Cash

Net Change in Cash at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$1.98B-86.2%
Amgen logo
AmgenAMGN
$2.91B+192%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
-$153.1M-125%
Xencor logo
XencorXNCR
-$40M-2,970%
AbbVie logo
AbbVieABBV
$4.16B+1,293%
Vor Biopharma logo
Vor BiopharmaVOR
-$226.61M-610%

Other financials

Income statement

See full
Revenue$3.7M
Operating income-$34.2M+2.0%
Net income-$24.4M-3.6%
EPS (diluted)-$0.39-2.6%

Balance sheet

See full
Cash & equivalents$51.8M-29.7%
Total debt$21.6M-4.6%
Total equity$941.5M-7.0%
Total assets$1.0B-2.1%

Cash flow

See full
Operating cash flow-$12.3M+27.5%
CapEx$273.0K-26.4%
Free cash flow-$12.6M+27.5%

Valuation

See full
Market cap$892.81M-36.1%
Enterprise value$862.55M-35.9%
P/S65×-84.6×

Profitability

See full
Operating margin-1,143.1%-65.1pp
Net margin-833.6%+0.9pp
FCF margin-571.6%+98.3pp

Returns & leverage

See full
Return on equity-11.7%+4.1pp
Debt / equity0.0×
Current ratio17×-41.5×

Where this comes from

Reported directly by Janux Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect.

The official record: Janux Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Janux Therapeutics's net change in cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Janux Therapeutics's net change in cash?
Janux Therapeutics (JANX) reported net change in cash of -$506K in Q1 2026.
How has Janux Therapeutics's net change in cash changed year-over-year?
Janux Therapeutics's net change in cash increased by 99.9% year-over-year, from -$356.86M to -$506K.
What does net change in cash mean?
Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.